Thomas Oakley, BA, MBA

Tom is an accomplished senior executive with over 30 years of domestic and international leadership experience in contract research, industrial products and consumer products businesses, the last 25 years of which have been spent in the contract research industry.  Tom has significant experience with mergers and acquisitions, business process redesign, performance improvement, start-ups (including raising investment capital) and turnarounds. Tom brings a broad range of CRO experience to PGI. Most recently, he was the COO of Inotiv, a position he assumed following the his role as the CEO of Seventh Wave Laboratories, where he led the sale of the business to BASI, which was later renamed as Inotiv.  Prior to Inotiv, he was the President and Chief Operating Officer of MPI Research, Inc., where he led improvements in operational efficiency, regulatory compliance and customer satisfaction. Prior to MPI, he was President and CEO of ChanTest Corporation, a provider of contract safety pharmacology testing and ion channel discovery screening services. Before ChanTest, Tom was the President and CEO of Bridge Laboratories, where he led the establishment of the first Western-quality preclinical toxicology CRO in China.  Earlier in his career, Tom held key operational and financial positions at Covance, where he was the Global VP of Finance and Administration for the Early Development Group, moving to become the VP and GM of North American Chemistry and then becoming the Global VP of Corporate Development. Tom holds a BA in Economics from Ripon College and a MBA in Finance, Accounting and Management from the J.L. Kellogg Graduate School of Management at Northwestern University. He is a veteran of the US Army.